沙库巴曲缬沙坦钠治疗射血分数保留心力衰竭的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Sacubatrol Valsartan Sodium in the treatment of heart failure with preserved ejection fraction (HFpEF). Methods A total of 78 patients with HFpEF admitted to our hospital from March 2018 to May 2019 were enrolled as study subjects. The participants were divided into the control group (n=39) and the experimental group (n=39) according to the random number table method. The control group was given routine treatment, while the experimental group was given Sacubatrol Valsartan Sodium. The therapeutic effect, cardiac function indexes (early diastolic velocity of mitral valve [E], early diastolic velocity of mitral annulus [e′], E/peak diastolic velocity of mitral valve [E/A], E/e′), N-terminal B-type natriuretic peptide (NT-proBNP), 6 min walking test distance (6MWT),quality of life score before and after treatment and incidence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group was 92.31%, which was higher than that in the control group accounting for 79.49%, with statistical difference (P＜0.05). There were no significant differences in cardiac function indexes, NT-proBNP, 6MWT and quality of life score between the two groups before treatment (P＞0.05). The E, e′ and E/A of the two groups after treatment were higher than those before treatment, the 6MWT was farther than that before treatment, with statistical differences (P＜0.05). The E/e′, NT-proBNP and quality of life scores in the two groups after treatment were lower than those before treatment, with statistical differences (P＜0.05). The E, e′and E/A in the experimental group after treatment were higher than those in the control group, the 6MWT was farther than that in the control group, with statistical differences (P＜0.05). The E/e′, NT-proBNP and quality of life scores in the experimental group after treatment were lower than those in the control group, with statistical differences (P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion The effect of Sacubatrol Valsartan Sodium is remarkable in the treatment of HFpEF. It can enhance cardiac function, and increase the exercise tolerance and quality of life in patients of HFpEF without increasing the incidence rate of adverse reaction, whcih is worthy of clinical application.

Key words： Sacubatrol Valsartan Sodium Heart failure with preserved ejection fraction N-terminal pro-brain natriuretic peptide Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DONG Zhi-hua
	TANG Min

Cite this article:

DONG Zhi-hua,TANG Min. Clinical effect of Sacubatrol Valsartan Sodium in the treatment of heart failure with preserved ejection fraction[J]. 中国当代医药, 2020, 27(16): 51-54.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I16/51

[1]	李世军，李小鹰.射血分数保留的心力衰竭诊断与管理[J].中华老年心脑血管病杂志，2017，19（12）：1324-1326.
[2]	Huang W，Chai SC，Lee SGS，et al.Prognostic factors after index hospitalization for heart failure with preserved ejection fraction[J].Am J Cardoil，2017，119（12）：2017-2020.
[3]	Suematsu Y，Jing W，Nunes A，et al.LCZ696 （Sacubitril/valsartan），an angiotensin-receptor neprilysin inhibitor，attenuates cardiac dypertrophy，fibrosis and vasculopathy in a rat model of chronic kidney disease[J].J Card Fail，2018，24（4）：266-275.
[4]	陈文文，刘燕琳，李振山，等.沙库巴曲缬沙坦在心衰治疗中的应用：从临床试验到真实世界[J].中国医院药学杂志，2018，38（21）：2286-2290.
[5]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[6]	吴少祯，吴敏.常见疾病的诊断与疗效判定（标准）[M].北京：北京中医药出版社，1999：561.
[7]	Bittner V，Weiner DH，Yusuf S，et al.Prediction of mortality and morbidity with 6-minute walk test in patients with left ventricular dysfunction[J].JAMA，1993，270（14）：1702-1707.
[8]	Rector TS，Cohn JN.Assessment of patient outcome with the minnesota living with heart failure questionnaire：reliability and validity during a randomized，double-blind，placebocontrolled trial of pimobendan[J].Am Heart J，1992，124（4）：1017-1025.
[9]	Sharma K，Kass DA.Heart failure with preserved ejection fraction：mechanisms，clinical features，and therapies[J].Circ Res，2014，115（1）：79-96．
[10]	Rodgers JE.Sacubitril/Valsartan：The newest addition to the toolbox for guideline-directed medical therapy of heart failure[J].Am J Med，2017，130（6）：635-639.
[11]	Khder Y，Shi V，Mc Murray J，et al.Sacubitril/Valsartan（LCZ696） in heart failure[J].Handb Exp Pharmacol，2017，243（22）：133-165.
[12]	Wang Y，Gu X，Fan W，et al.Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction[J].Am J Transl Res，2016，8（1）：239-245.
[13]	Chen CH.Critical questions about PAR-ADIGM-HF and the future[J].Acta Cardiol Sin，2016，32（4）：387-396.
[14]	Von Lueder TG，Sangaralionham SJ，Wang BH，et al.Renin-angiotensin blockade combined with natriuretic peptide system augmentation：novel therapeutic concepts to combat heart failure[J].Circ Heart Fail，2013，6（3）：594-605.
[15]	石艳刚.芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果[J].中国当代医药，2018，25（31）：56-58，62.
[16]	周红，黄思兵.沙库巴曲缬沙坦治疗慢性心功能不全的临床效果观察[J].中国当代医药，2018，25（19）：51-53.
[17]	Solomon SD，Claggett B，Desai AS，et al.Influence of ejection fraction on outcomes and efficacy of Sacubitril/Valsartan （LCZ696） in heart failure with reduced ejection fraction Clinical perspective[J].Circ Heart Fail，2016，9（3）：e002744.
[18]	吴立华，刘倩，高丽娜，等.NT-proBNP 评估射血分数保留心力衰竭病人病情及预后的临床研究[J].中西医结合心脑血管病杂志，2019，17（11）：1688-1690.
[19]	Potter LR.Natriuretic peptide metabolism，clearance and degradation[J].FEBS J，2011，278（11）：1808-1817.
[20]	Pagel-Langenickel I.Evolving role of natriuretic peptides from diagnostic tool totherapeutic modality[J].Adv Exp Med Biol，2018，1067（10）：109-131.